Status:
COMPLETED
The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Cytomegalovirus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This pilot study is to assess whether using CytoGam® in combination with ganciclovir is more effective in reducing the CMV viral load over time, as compared to standard treatment with IV ganciclovir o...
Eligibility Criteria
Inclusion
- Renal or renal/pancreas transplant patients who are diagnosed with symptomatic CMV infection
- receiving no more than 48 hrs of therapy prior to study enrollment
Exclusion
- serum creatinine \<2.2 at the time of enrollment
- no prior use of CMV IgG
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00214240
Start Date
January 1 2000
End Date
April 1 2007
Last Update
July 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792